Clinical trial NCT00229424 (phase 3, status: completed)
Conditions: gastroesophageal reflux
ICD codes: K21.9, K21.00, K21.01
Drugs: lafutidine, famotidine
SMILES: [H]\C(COC1=NC=CC(CN2CCCCC2)=C1)=C(/[H])CN=C(O)CS(=O)CC1=CC=CO1, NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1
Eligibility criteria:

        Inclusion Criteria:

          -  Age 20 and over (at the time of consent given)

          -  Gender and inpatient or outpatient: Irrelevant

          -  Patients diagnosed with Grade A or Grade B mild reflux oesophagitis (according to the
             Los Angels classification) through endoscopic test

          -  Patients who complained about "heartburn symptom" within one week prior to the
             enrollment

        Exclusion Criteria:

          -  Patients whose "heartburn symptom" has been disappeared (not been observed at all)
             during the observation period (Check before official enrollment)

          -  Patients in ill compliance with dosing the investigational product for the observation
             period (Not more than 75%, check from the patient dairy before official enrollment)

          -  Patients the investigator/sub-investigator assessed difficult to complete the patient
             diary during the treatment period because the patient diary for the observation period
             has too many deficiencies. (Check before official enrollment)

          -  Patients with complication of gastric/duodenal ulcer (scarring acceptable)

          -  Patients with complication of Barrett lining over the site exceeding 3 cm of
             esophageal distal portion

          -  Patients who have received the normal dose of H2 receptor antagonist or proton pump
             inhibitor (PPI) for 8 weeks in vain

          -  Patients whose Helicobacter pylori was successfully eradicated within 24 weeks

          -  Patients with medical history of upper gastrointestinal tract excision

          -  Patients with complication of angina pectoris

          -  Patients who have received treatment of any other investigational product within 12
             weeks

          -  Patients who showed any of the following values at the laboratory tests before
             official enrollment: Hemoglobin: < 9.5 g/dL, WBC: < 3,000/mm^3, Thrombocytes: <
             75,000/mm^3, AST and ALT : ≥ 100 IU/L, Creatinine: ≥ 1.5 mg/dL These should be
             assessed using the current test values from the blood drawn within 4 weeks prior to
             official enrollment.

          -  Patients with complication of serious cardiac disorder (Grade 3 or above under PAB/SD
             Notification No. 80) For example, patients with triplet or more ventricular premature
             contractions (multi-sources) or using a pacemaker

          -  Patients with medical history of serious hypersensitivity to drugs (Grade 3 or above
             under PAB/SD Notification No. 80)

          -  Patients who receive treatment of cancer

          -  Women of confirmed or potential pregnancy, those who wish to become pregnant, and
             breast feeding women

          -  Patients having any other condition that, in the opinion of the
             investigator/sub-investigator disqualifies them for the trial